C20T5

**C20T5** is a Cannatrek medicinal cannabis oral oil product marketed as a CBD-predominant formulation containing cannabidiol and delta-9-tetrahydrocannabinol. The product designation denotes a formulation containing approximately 20 mg/mL cannabidiol and 5 mg/mL delta-9-tetrahydrocannabinol. It was evaluated by Murdoch Childrens Research Institute in the randomized pilot trial NCT05615389 in children and young people receiving palliative care for non-oncological conditions. Its therapeutic activity is mediated principally through cannabinoid receptor signaling, with delta-9-tetrahydrocannabinol acting as a partial agonist at cannabinoid receptors 1 and 2, while cannabidiol has broader modulatory pharmacology across the endocannabinoid system and other signaling pathways.

Brand names

C20T5 Ruby CBD OilC-20T5 Ruby CBD OilC 20T5 Ruby CBD OilCannatrek C20T5 Ruby

Other names

C20T5C-20T5C 20T5